Core Viewpoint - The company is investing 1 billion yuan in a synthetic biology manufacturing project to enhance production capacity, improve efficiency, and maintain market competitiveness [1] Group 1: Investment and Project Details - The project will be constructed in three phases, funded entirely by the company's own resources [1] - The investment aims to address production capacity and efficiency bottlenecks, as existing production lines are insufficient to meet market demand [1] Group 2: Strategic Objectives - The project will strengthen the company's technological leadership by introducing advanced, energy-efficient, and highly automated production equipment [1] - The initiative is part of a core strategy to control costs, particularly in energy consumption, labor, and maintenance, by optimizing production processes and reducing operational costs [1]

Core Viewpoint - The company is focused on the industrial application of new materials, leveraging advanced coating technology to establish a diversified industry layout in "new energy + semiconductor" sectors [1] Group 1: Business Strategy - The company acknowledges the suggestion from investors to concentrate on its core business and aims to strengthen its position in niche markets [1] - The company is committed to the industrialization of new materials, indicating a strategic focus on innovation and application [1] Group 2: Product Applications - Core products of the company are currently applied in various fields including lithium batteries, perovskite solar cells, display panels, and energy storage [1]

Performance Forecast - The company expects a net loss of between 30 million to 45 million yuan for the first half of 2025, compared to a loss of 33.05 million yuan in the same period last year [1] - The expected loss after deducting non-recurring gains and losses is projected to be between 27 million to 40.5 million yuan, compared to a loss of 26.5 million yuan in the previous year [1] - The estimated basic earnings per share are expected to be a loss of 0.0340 to 0.0510 yuan per share, compared to a loss of 0.0376 yuan per share last year [1] - The anticipated operating revenue is between 150 million to 190 million yuan, down from 202.58 million yuan in the same period last year [1] Reasons for Performance Change - The decline in sales revenue of the company's core products is attributed to stricter medical insurance cost control measures, which have negatively impacted overall profitability [1] Financial Reporting and Audit - The financial data in the performance forecast has not been audited by an accounting firm [1] - The company has been in a pre-restructuring process, and there is uncertainty regarding its ability to enter the restructuring process [2] - The 2024 annual audit report from the accounting firm highlighted significant uncertainties regarding the company's ability to continue as a going concern [2]